logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA).

Ashman says it's a significant first deal for them and provides third-party validation of its technology.

Quick facts: SkinBioTherapeutics PLC

Price: 16.875 GBX

AIM:SBTX
Market: AIM
Market Cap: £21.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis. The pair plan to carry out a human study on mild to moderate...

on 26/2/20

2 min read